Direxion Daily Pharmaceutical & Medical Bull 3X ETF
The Direxion Daily Pharmaceutical & Medical Bull 3X ETF seeks daily investment results, before fees and expenses, of 300% of the performance of the S&P Pharmaceuticals Select Industry Index. There is no guarantee the fund will achieve its stated investment objective.
PILL
Documents & Downloads
This leveraged ETF seeks a return that is 300% the return of its benchmark index for a single day. The fund should not be expected to provide three times the return of the benchmark’s cumulative return for periods greater than a day.
Pricing & Performance
NAV and Market Price information as of 06/04/2026.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Since Inception (11/15/2017) | Expense Ratio* (Gross / Net%) | |
|---|---|---|---|---|---|---|---|---|---|
| PILL NAV | 1.31 | -2.09 | 1.56 | 139.06 | 20.70 | -9.94 | — | -7.19 | 1.22 / 0.98* |
| PILL Market Close | 1.22 | -2.39 | 1.42 | 140.09 | 20.55 | -9.86 | — | -7.15 | 1.22 / 0.98* |
As of May 31, 2026
The Primary Listing Exchange is the NYSE Arca, Inc.
*The Net Expense Ratio includes management fees, other operating expenses and Acquired Fund Fees and Expenses. If Acquired Fund Fees and Expenses were excluded, the Net Expense Ratio would be 0.95%. The Fund’s adviser, Rafferty Asset Management, LLC (“Rafferty”) has entered into an Operating Expense Limitation Agreement with the Fund. Under the Operating Expense Limitation Agreement, Rafferty has contractually agreed to waive all or a portion of its management fee and/or reimburse the Fund for Other Expenses through September 1, 2027, to the extent that the Fund’s Total Annual Fund Operating Expenses exceed 0.95% of the Fund’s average daily net assets (excluding, as applicable, among other expenses, taxes, swap financing and related costs, acquired fund fees and expenses, dividends or interest on short positions, other interest expenses, brokerage commissions and extraordinary expenses). If these expenses were included, the expense ratio would be higher.
Index Information
The S&P Pharmaceuticals Select Industry Index (SPSIPHTR) is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the Global Industry Classification Standard (GICS) pharmaceuticals sub-industry. One cannot invest directly in an index.
Index Top Ten Holdings
| % of Total | |
|---|---|
| Enliven Therapeutics Inc | 2.45% |
| Corcept Therapeutics | 2.29% |
| Terns Pharmaceuticals Shares | 2.16% |
| Perrigo Company Plc | 2.10% |
| Axsome Thera Cmn Stk | 2.03% |
| Innoviva Inc | 1.99% |
| Merck & Company Inc | 1.99% |
| Pfizer | 1.97% |
| Royalty Pharma A | 1.97% |
| Elanco Animal Health Inc | 1.96% |
Index Sector Weightings
| % of Total | |
|---|---|
| Pharmaceuticals | 100.00% |
Strategy & Benefits
You know that TRADING is different than investing. But the opportunity to take advantage of short-term trends is only won, if you get the direction right.
Whether you’re a bull or a bear, Direxion is with you. Our leveraged ETFs are powerful tools built to help you:
- Magnify your short-term perspective with daily 3X leverage
- Go where there’s opportunity, with bull and bear funds for both sides of the trade; and
- Stay agile – with liquidity to trade through rapidly changing markets
Leveraged and inverse ETFs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying index over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments.
Distributions
| Record Date | Ex Date | Pay Date | Income Dividend | Short-Term Capital Gain | Long-Term Capital Gain | Return of Capital | Expand |
|---|---|---|---|---|---|---|---|
| 03/24/2026 | 03/24/2026 | 03/31/2026 | 0.01085 | — | — | — | |
| 12/23/2025 | 12/23/2025 | 12/31/2025 | 0.03265 | — | — | — | |
| 09/23/2025 | 09/23/2025 | 09/30/2025 | 0.00985 | — | — | — | |
| 06/24/2025 | 06/24/2025 | 07/01/2025 | 0.02449 | — | — | — | |
Record Date03/24/2026 Ex Date03/24/2026 Pay Date03/31/2026 Income Dividend0.01085 Short-Term Capital Gain— Long-Term Capital Gain— Return of Capital— Record Date12/23/2025 Ex Date12/23/2025 Pay Date12/31/2025 Income Dividend0.03265 Short-Term Capital Gain— Long-Term Capital Gain— Return of Capital— Record Date09/23/2025 Ex Date09/23/2025 Pay Date09/30/2025 Income Dividend0.00985 Short-Term Capital Gain— Long-Term Capital Gain— Return of Capital— Record Date06/24/2025 Ex Date06/24/2025 Pay Date07/01/2025 Income Dividend0.02449 Short-Term Capital Gain— Long-Term Capital Gain— Return of Capital— | |||||||
Documents
Documents & Downloads
Browse Other Funds
Subscribe to Newsletters & Operational Updates
Sign up for email and/or text of the important news, including:
- Fund updates including splits, distributions, launches, and other corporate actions
- Educational events, such as web seminars and conferences
- Our latest research and industry trends
Learn About Leveraged & Inverse ETFs
Trading is different than investing. Use our insights and educational resources to make sure you’re ready to trade in Direxion’s Leveraged and Inverse ETFs.


